PE20120331A1 - Agentes medicinales unidos a dipeptido - Google Patents

Agentes medicinales unidos a dipeptido

Info

Publication number
PE20120331A1
PE20120331A1 PE2011001237A PE2011001237A PE20120331A1 PE 20120331 A1 PE20120331 A1 PE 20120331A1 PE 2011001237 A PE2011001237 A PE 2011001237A PE 2011001237 A PE2011001237 A PE 2011001237A PE 20120331 A1 PE20120331 A1 PE 20120331A1
Authority
PE
Peru
Prior art keywords
alkyl
group
dipeptide
medicinal agent
breaking
Prior art date
Application number
PE2011001237A
Other languages
English (en)
Inventor
Richard D Dimarchi
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of PE20120331A1 publication Critical patent/PE20120331A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPLEJO QUE COMPRENDE: (I) UN GRUPO DIPEPTIDO DE AUTO ROTURA NO ENZIMATICA DE ESTRUCTURA GENERAL (A-B) DONDE: A ES UN AMINOACIDO O HIDROXIL ACIDO; B ES UN AMINOACIDO N-ALQUILADO; (II) UN AGENTE MEDICINAL (Q) TAL COMO UN PEPTIDO BIOACTIVO QUE ESTA UNIDO COVALENTEMENTE AL GRUPO DE AUTO ROTURA; EN DONDE EL GRUPO DE AUTO ROTURA ESTA UNIDO A DICHO AGENTE MEDICINAL A TRAVES DE UN ENLACE DE AMIDA ENTRE B Y UNA AMIDA DEL AGENTE MEDICINAL; (III) UN POLIMERO DE DEPOSITO TAL COMO POLIETILENGLICOL QUE TIENE UN PESO MOLECULAR ENTRE 40.000 A 80.000 QUE ESTA UNIDO A LA CADENA LATERAL A O B A TRAVES DE UNA UNION A UN GRUPO ACILO O GRUPO ALQUILO C16-C18. EL GRUPO DIPEPTIDO COMPRENDE LA ESTRURA DE FORMULA (i) DONDE: R1, R2, R4 Y R8 SE SELECCIONAN INDEPENDIENTEMENTE DE H, ALQUILO C1-C18, ALQUENILO C2-C18, (ALQUILO C1-C18)OH, (ALQUILO C1-C18)SH, ENTRE OTROS; R3 ES ALQUILO C1-C18, (ALQUILO C1-C18)NH2, (ALQUILO C0-C4)CICLOALQUILO C3-C6, (ALQUILO C0-C4)(HETEROCICLICO C2-C5), ENTRE OTROS. DICHO COMPLEJO MEJORA LA SOLUBILIDAD, ESTABILIDAD Y/O FARMACOCINETICA DEL PROFARMACO
PE2011001237A 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido PE20120331A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13922708P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
PE20120331A1 true PE20120331A1 (es) 2012-04-14

Family

ID=42316744

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001237A PE20120331A1 (es) 2008-12-19 2009-12-18 Agentes medicinales unidos a dipeptido

Country Status (13)

Country Link
US (1) US20110237493A1 (es)
EP (1) EP2376098A4 (es)
JP (2) JP2012512898A (es)
KR (1) KR20110114568A (es)
CN (1) CN102300580A (es)
AU (1) AU2009335711A1 (es)
CA (1) CA2747195A1 (es)
IL (1) IL213341A0 (es)
MX (1) MX2011006527A (es)
PE (1) PE20120331A1 (es)
RU (1) RU2578591C2 (es)
SG (1) SG172290A1 (es)
WO (1) WO2010080605A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
ES2628063T3 (es) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
KR20090119876A (ko) 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
MX2010004298A (es) 2007-10-30 2010-05-03 Univ Indiana Res & Tech Corp Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
JP5669582B2 (ja) 2007-10-30 2015-02-12 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴンアンタゴニスト
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
CA2727161A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
MX2010013453A (es) 2008-06-17 2011-01-21 Univ Indiana Res & Tech Corp Agonistas mezclados basados en gip para el tratamiento de desordenes metabolicos y obesidad.
CN103641907A (zh) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
KR20110110174A (ko) 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭
WO2010080606A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Insulin analogs
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
EP2528618A4 (en) 2010-01-27 2015-05-27 Univ Indiana Res & Tech Corp GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
JP6050746B2 (ja) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
WO2011162968A1 (en) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Dipeptide linked medicinal agents
CA2803164C (en) 2010-06-24 2018-08-21 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2588126A4 (en) 2010-06-24 2015-07-08 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY AMIDE PEPTIDE PRODRUGS
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
KR101972617B1 (ko) 2011-06-22 2019-04-25 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-항진제들
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
BR112014007124A2 (pt) * 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
WO2013096386A1 (en) 2011-12-20 2013-06-27 Indiana University Research And Technology Corporation Ctp-based insulin analogs for treatment of diabetes
CN103172726B (zh) * 2011-12-22 2017-06-13 杭州淳泰科技有限公司 胰泌素类似物及其制备方法和用途
WO2013127779A1 (en) 2012-03-01 2013-09-06 Novo Nordisk A/S Glp-1 prodrugs
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
CN104981251B (zh) 2012-09-26 2018-03-20 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
BR112015023071A2 (pt) 2013-03-14 2017-07-18 Univ Indiana Res & Tech Corp conjugados de insulina-incretina
CN112043835B (zh) 2013-12-06 2022-10-21 韩捷 用于含氮和羟基的药物的生物可逆引入基团
CN107001441A (zh) 2014-09-24 2017-08-01 印第安纳大学研究及科技有限公司 脂质化的基于酰胺的胰岛素前药
JP6657230B2 (ja) 2014-09-24 2020-03-04 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション インクレチン−インスリンコンジュゲート
JP2019525947A (ja) 2016-06-01 2019-09-12 エムスリー・バイオテクノロジー・インコーポレイテッドＭ３ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 化合物
BR112022024058A2 (pt) * 2020-05-26 2022-12-20 Univ Indiana Res & Tech Corp Análogos de pth para o tratamento de hipoparatireoidismo
BR112023000270A2 (pt) 2020-07-22 2023-01-31 Novo Nordisk As Composto, composição farmacêutica, e, peptídeo
MX2023004672A (es) 2020-11-06 2023-07-20 Novo Nordisk As Profármacos de péptido tipo glucagón humano 1 (glp-1) y usos de los mismos.
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
TW202346324A (zh) 2022-05-10 2023-12-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2024110614A1 (en) 2022-11-25 2024-05-30 Novo Nordisk A/S Oral administration of peptide therapeutics, such as glp-1

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) * 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
US4741897A (en) * 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DE19828113A1 (de) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
US20030236190A1 (en) * 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
CA2367856C (en) * 1999-03-29 2013-10-15 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
AUPQ661800A0 (en) * 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
GB2382346B (en) * 2000-08-04 2004-08-11 Dmi Biosciences Inc Method of synthesizing diketopiperazines
WO2002026265A2 (en) * 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
EP1243276A1 (en) * 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
DK2322631T3 (en) * 2001-04-19 2015-01-12 Scripps Research Inst Methods and compositions for the production of orthogonal tRNA-aminoacyl-tRNA syntetasepar
JP2005508895A (ja) * 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
US7238656B2 (en) * 2001-08-29 2007-07-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Protective factors against inflammation, burns and noxious stimuli
MXPA04006084A (es) * 2001-12-20 2005-03-31 Lilly Co Eli Molecula de insulina que tiene una accion en el tiempo prolongada.
FR2842209B1 (fr) * 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
EP1605897B1 (en) * 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
CA2521784C (en) * 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
BRPI0414539B8 (pt) * 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
WO2005035003A2 (en) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CA2621847A1 (en) * 2005-09-08 2007-03-15 Shire Llc Prodrugs of t3 and t4 with enhanced bioavailability
CN101432025B (zh) * 2006-03-21 2012-04-04 安米林药品公司 肽-肽酶抑制剂结合物及其使用方法
EP2069396B1 (en) * 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
KR20090119876A (ko) * 2007-02-15 2009-11-20 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
CN101983066B (zh) * 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
KR20110110174A (ko) * 2008-12-19 2011-10-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭

Also Published As

Publication number Publication date
MX2011006527A (es) 2011-08-17
WO2010080605A1 (en) 2010-07-15
JP2012512898A (ja) 2012-06-07
CN102300580A (zh) 2011-12-28
KR20110114568A (ko) 2011-10-19
EP2376098A1 (en) 2011-10-19
RU2011129764A (ru) 2013-01-27
IL213341A0 (en) 2011-07-31
RU2578591C2 (ru) 2016-03-27
US20110237493A1 (en) 2011-09-29
SG172290A1 (en) 2011-07-28
AU2009335711A1 (en) 2010-07-15
CA2747195A1 (en) 2010-07-15
EP2376098A4 (en) 2014-06-11
JP2016028082A (ja) 2016-02-25

Similar Documents

Publication Publication Date Title
PE20120331A1 (es) Agentes medicinales unidos a dipeptido
CY1118243T1 (el) Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα
PE20080093A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
PE20150041A1 (es) Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
ECSP099638A (es) Nuevo compuesto de adenina
ES2422204T3 (es) Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS)
ES2567418T3 (es) Derivados citotóxicos de benzodiazepina
PE20130578A1 (es) Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa
SV2006002110A (es) Compuestos terapeuticos ref. pc32293a
PE20120062A1 (es) Derivados de 1-bencil-2-amino-tetralina como inhibidores del transportador de glicina glyt1
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
PE20121311A1 (es) Derivados del acido carbamoil-metil-amino-acetico sustituido como inhibidores de nep novedosos
PE20070171A1 (es) GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
PE20091783A1 (es) Anticuerpos anti-factor d humanizados
PE20081834A1 (es) Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
PH12012501881A1 (en) 4-amino-4- oxobutanoyl peptides as inhibitors of viral replication
DOP2010000046A (es) Compuestos de biciclolactama sustituida
UY30051A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20141585A1 (es) Composicion farmaceutica estabilizada a base de un compuesto no petidico
AU2005265164A2 (en) Non-natural amino acids
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas

Legal Events

Date Code Title Description
FC Refusal